• 
  Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04519993⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04176638⟩
• 
  Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, 2023, ⟨10.1002/ijc.34636⟩. ⟨hal-04154476⟩
• 
  Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
• 
  Jordi Remon, Nicolas Girard, Silvia Novello, Javier de Castro, Laurence Bigay-Game, et al.. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer, 2021, ⟨10.1016/j.cllc.2021.07.008⟩. ⟨hal-03524401⟩
• 
  Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
• 
  Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, et al.. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. ESMO Open, 2022, European Society for Medical Oncology, 7, pp.100468. ⟨10.1016/j.esmoop.2022.100468⟩. ⟨hal-04567217⟩
• 
  M. Brahmi, T. Lesluyes, A. Dufresne, M. Toulmonde, A. Italiano, et al.. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas.. ESMO Open, 2021, ESMO Open, 6 (1), pp.100037. ⟨10.1016/j.esmoop.2020.100037⟩. ⟨hal-04552489⟩
• 
  Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer. Clinical Cancer Research, 2023, 29 (13), pp.2401-2409. ⟨10.1158/1078-0432.CCR-23-0046⟩. ⟨inserm-04552345⟩
• 
  Laurence Brugières, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, et al.. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS-crizotinib trial. European Journal of Cancer, 2023, 191, pp.112984. ⟨10.1016/j.ejca.2023.112984⟩. ⟨hal-04228222⟩
• 
  Julie Blanchi, Sofiane Taleb, Arnaud Bayle, Benjamin Verret, Maud Toulmonde, et al.. Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas. Cancer Communications, 2023, 43 (9), pp.1051 - 1054. ⟨10.1002/cac2.12461⟩. ⟨inserm-04538185⟩
• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Jean-Marc Classe, Gilles Dolivet, Serge Evrard, Gwenael Ferron, Fabrice Lécuru, et al.. Recommandations de la Société française de chirurgie oncologique (SFCO) pour l’organisation de la chirurgie oncologique durant l’épidémie de COVID-19. Bulletin du Cancer, 2020, 107 (5), pp.524-527. ⟨10.1016/j.bulcan.2020.03.010⟩. ⟨hal-02988833⟩
• 
  Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid, 2023, 33 (9), pp.1124-1129. ⟨10.1089/thy.2023.0240⟩. ⟨inserm-04527070⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
• 
  Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, et al.. Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study. Molecular Cancer, 2023, 22 (1), pp.176. ⟨10.1186/s12943-023-01878-9⟩. ⟨inserm-04521346⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩

247

270